The molecular heterogeneity of the precancerous breast affects drug efficacy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Prevention Research

Background:

• Targeted therapies are most effective when tumors harbor specific molecular aberrations.
• The principle of targeting molecular aberrations has not been extensively studied in cancer prevention.
• Cancer progression involves molecular heterogeneity, suggesting timing of intervention may be critical.

Purpose of the Study:

• To investigate if the efficacy of agents targeting precancerous states varies with the timing of treatment relative to molecular changes.
• To explore the relationship between molecular progression and the effectiveness of targeted agents in cancer prevention.

Main Methods:

• Utilized an MCF10A cell line model to simulate the multi-step progression to triple-negative breast cancer (TNBC).
• Analyzed global proteomic patterns at different stages of neoplastic progression.
• Correlated the growth-inhibitory effects of selected agents with the underlying molecular stage.

Main Results:

• Most protein alterations in breast cancer progression occur during the normal-to-atypia (preneoplasia) transition.
• Efficacy of AKT/MEK pathway inhibitors correlated with specific pathway activation levels.
• Fluvastatin showed increased efficacy earlier in the progression model, while non-specific agents like aspirin and metformin were ineffective across stages.

Conclusions:

• Treatment efficacy for targeted cancer prevention agents depends on the molecular heterogeneity of precancerous tissue.
• Timing of intervention relative to molecular progression is crucial for maximizing the effectiveness of targeted therapies in cancer prevention.
• This study provides a proof-of-principle for considering molecular timing in the development of cancer prevention strategies.